Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI397 in Advanced Malignancies
NCT05245916Phase 1Withdrawn
- Sponsor
- Innovent Biologics
- Start
- Apr 2022
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of IBI397 in solid tumor (advanced stage) and lymphoma (3 arms), sponsored by Innovent Biologics. Primary endpoints: Number of patients with treatment related adverse events and Percentage of Subjects with Dose-Limiting Toxicities. Planned start Apr 2022; status: withdrawn.
02
Drugs
IBI397
03
Conditions
solid tumor (advanced stage)lymphoma
Beyond the preview
Go deeper on NCT05245916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05245916.